SK Bioscience Co.,Ltd
Financials
Valuation Metrics
SK Bioscience Co.,Ltd's Market Cap is ₩2.8T. At end of 2025 it was ₩3.8T. Ranked #150 of 2,414 in KR market (top 6%), #131 of 781 on KOSPI (top 17%), #9 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 4%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.77T KRW | KR#150/2,414 Sec#9/231 |
| Revenue | 659.27B KRW | KR#522/2,414 Sec#21/231 |
| Net Income | -85.57B KRW | KR—/2,414 Sec—/231 |
| Total Assets | 2.98T KRW | KR#241/2,414 Sec#7/231 |
| Net Assets | 2.01T KRW | KR#186/2,414 Sec#5/231 |
| Employees | 1,021 | KR#253/2,414 Sec#18/231 |
| Value | ||
| P/B | 1.38x | KR#1,756/2,414 Sec#121/231 |
| P/S | 4.21x | KR#2,113/2,414 Sec#135/231 |
| FCF Yield | -2.91% | KR—/2,414 Sec—/231 |
| Profitability | ||
| ROE | -4.26% | KR#1,769/2,414 Sec#125/231 |
| ROA | -2.87% | KR#1,824/2,414 Sec#129/231 |
| Op. Margin | -19.91% | KR#2,112/2,414 Sec#144/231 |
| Revenue Growth | 23.25% | KR#494/2,414 Sec#46/231 |
| Financial Health | ||
| Debt Ratio | 48.58% | KR#940/2,414 Sec#105/231 |
| Total Debt | 1.08T KRW | KR#198/2,414 Sec#6/231 |
| FCF | -80.58B KRW | KR#2,114/2,414 Sec#209/231 |
| Cash | 130.22B KRW | KR#388/2,414 Sec#18/231 |
| Current Ratio | 3.60x | KR#440/2,414 Sec#66/231 |
| Performance | ||
| 1Y Return | -23.48% | KR#1,279/2,414 Sec#92/231 |
| 1M Return | -3.94% | KR#887/2,414 Sec#78/231 |
| From 52W High | -42.33% | KR#882/2,414 Sec#64/231 |
| 1Y MDD | -45.92% | KR#809/2,414 Sec#63/231 |
| Trading | ||
| Volume | 75,108 shares | KR#1,109/2,414 Sec#112/231 |
| Trading Value | 2.65B KRW | KR#512/2,414 Sec#46/231 |
| Foreign Own. | 5.98% | KR#731/2,414 Sec#65/231 |
| Per Share | ||
| EPS | -1,091 KRW | KR—/2,414 Sec—/231 |
| BPS | 25,580 KRW | KR#440/2,414 Sec#31/231 |
Company Info
SK Bioscience was established in 2018 through a spin-off of SK Chemical's vaccine business division, officially entering the global market in 2024 with the acquisition of a German CDMO specialized company. Its core businesses are vaccine/biopharmaceutical research and development, production, sales, and CDMO, with revenue composed of 18.4% proprietary vaccines, 7.6% product sales, and 74.0% CDMO. The company develops disease prevention and treatment pharmaceuticals using diverse vaccine production technologies. SK Bioscience is executing a strategy to grow into a Global Top 10 Vaccine Company and is headquartered in Seongnam-si, Gyeonggi-do.